Skip to content

Respiratory Function 3 Months After Hospital Discharge in Critically Ill COVID-19 Patients

Respiratory Function 3 Months After Hospital Discharge in Critically Ill COVID-19 Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05249842
Enrollment
60
Registered
2022-02-22
Start date
2020-04-01
Completion date
2022-06-30
Last updated
2022-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

COVID-19, Critical Care, Survivors, Pulmonary function test, Physical component summary

Brief summary

The objective of this single-center retrospective observational study is to describe spirometric abnormalities and their impact on 6-minute walk test (6MWT) and the physical component summary (PCS) of the SF-36 quality of life instrument.at least 3 months later discharge hospital.

Detailed description

Background: The COVID-19 pandemic has already affected more than 400 million people worldwide and resulted in at least 6 million deaths. The disease has also resulted in a growing population of individuals, with both physical and mental sequelae. Pulmonary sequelae have been the subject of several studies because the lung is the main target organ of the disease. However, there is still unknown data about the pulmonary manifestations and their spirometric patterns after a critical illness and also its consequences in quality of life. Purpose: Up to 20% of COVID-19 patients develop severe forms of the disease and require ICU admission. Most of these patients at hospital discharge still have several limitations that impact on quality of life. Some studies have analyzed pulmonary functional alterations after a variable period of time and have found results that vary from the absence of functional alterations to restrictive and diffusion impairment. Few studies have analyzed changes in small airways, and those that have evaluated have found no changes. The objective of this single-center retrospective observational study is to describe spirometric abnormalities and their impact on 6-minute walk test (6MWT) and the physical component summary (PCS) of the SF-36 quality of life instrument.at least 3 months later discharge hospital. Primary outcome: To describe spirometric patterns associated to severe COVID-19 survivors at least 3 months after hospital discharge. Secondary outcomes: Correlate the results of the spirometric evaluation with the 6-minute walk test (6MWT) and the physical component summary (PCS) of the SF-36 quality of life instrument. Methods: An observational retrospective study will be conducted, including all 18 years and older patients with severe COVID-19, confirmed by real-time reverse transcriptase-polymerase chain reaction., admitted to a 35- bed intensive care unit of a tertiary hospital from April 2020 to October 2021. Pediatric, pregnant or breastfeeding women and palliative care patients as well as chronic obstructive pulmonary disease and symptomatic asthmatic patients will be excluded. Population is estimated at 60 patients. Data collecting will be finished in February 2022. Patients routinely are assessed after at least 3 months after hospital discharge in our multidisciplinary follow-up clinic. A trained research team will routinely apply the 6 minute walk test (6MWT), a Pulmonary Function Test (PFT) and Short Form Health Survey 36 (SF-36) physical component summary (PCS) of SF-36

Interventions

DIAGNOSTIC_TESTSpirometric evaluation

Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75

DIAGNOSTIC_TESTPhysical component summary

Evaluation of the physical component summary of SF-36 quality of life

DIAGNOSTIC_TEST6MWT

6 minute walk test

Sponsors

Hospital Sao Domingos
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All 18 years and older patients with severe COVID-19, confirmed by real-time reverse transcriptase-polymerase chain reaction., admitted to a 15- bed intensive care unit of a tertiary hospital from April 2020 to October 2021.

Exclusion criteria

* \< 18 years old * Pregnant * Breastfeeding * Chronic pulmonary obstructive disease * Symptomatic asthma

Design outcomes

Primary

MeasureTime frameDescription
Forced vital capacity (FVC)3 months after hospital dischargeForced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration, Measured in liters. Normal value \> 80% of predicted for age, sex, heigth and ethnicity
Forced expiratory volume in 1 second (FEV1)3 months after hospital dischargeFEV1 is the volume of air that can forcibly be blown out in first 1 second, after full inspiration. Measured in liters. Normal value \> 80%. of predicted for age, heigth and ethnicity.
FEV1 / FVC Ratio3 months after hospital dischargeRepresents the proportion of vital capacity that the patients are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). The result of this ratio is expressed as FEV1%. Normal values are \> 75%.of predicted that depend on age, sex, height, and ethnicity
Forced mid-expiratory flow (FEF25-75%)3 months after hospital dischargeDefined as the mean forced expiratory flow during the middle half of the FVC . Normal value \> 65% of predictedf for age, sex, heigth and ethnicity

Secondary

MeasureTime frameDescription
Physical Component Summary (PCS) of Short Form- 36 (SF-36) Instrument3 months after hospital dischargePCS is composed of four scales assessing physical function, role limitations caused by physical problems, bodly pain and general health. The result scale ranges from 0 to 100, with 0 being the worst result and 100 the best.
6 Minute Walk Test3 months after hospital dischargeThe patient is placed on a flat, rigid area 30 meters long and instructed to walk the longest tolerable distance for 6 minutes. Measured in meters. The result is given as a percentage of the normal predicted value for age, sex, height and weight calculated by the Enright and Sherril equation.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026